Hypogonadism Market Report

• The Hypogonadism Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• The Hypogonadism Market companies developing therapies include - AbbVie Inc., Pfizer Inc., Endo Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Bayer AG, Ferring Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Viatris Inc, and others.

Hypogonadism Market and Epidemiology Analysis

• Hypogonadism is often underreported, improperly diagnosed, and overtreated. The condition can be hypergonadotropic (primary, resulting when the gonads fail) or hypogonadotropic.
• The Endocrine Society Clinical Practice Guideline defines male hypogonadism as “a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone due to disruption of one or more levels of the hypothalamic-pituitary-testicular axis.
• Patients with hypogonadism are typically treated with sex steroid replacement. The goals of treatment are: to promote the development of and maintain secondary sexual characteristics and normal sexual function, to build and sustain normal bone and muscle mass, and to assist in the proper psychosocial adjustment of adolescents with hypogonadism.
• Testosterone replacement therapy is a well-tolerated and established treatment for hypogonadism, providing excellent clinical and biochemical relief from the effects of sex steroid deficiency.
• Estrogen and progesterone are commonly used in girls and women for various medical reasons, including managing menopausal symptoms and in some cases, hormone injections or pills may also be used to stimulate ovulation.
• Asymptomatic hypogonadal patients do not require treatment. Only patients with symptoms possibly associated with low testosterone levels should be considered candidates for therapy.
• Oral testosterone supplements, such as methyltestosterone, are not recommended due to their associated liver toxicity, including jaundice, cholestasis, and abnormal hepatic function tests.
• Clomiphene citrate is an effective therapy for both biochemical and clinical male hypogonadism through a unique mechanism of action.
• Human chorionic gonadotropin (hCG) works similarly to clomiphene in that it will stimulate testosterone production by the Leydig cells of the testes without affecting sperm counts or spermatogenesis. hCG is similar to luteinizing hormone but has a much longer half-life (36 hours compared to 30 minutes), which is why it is often the preferred agent used in symptomatic testosterone-deficient men with hypogonadotropic hypogonadism.
• Very few biopharmaceutical companies are actively developing novel therapies for hypogonadism, with a notable example being RPN-001 (leflutrozole)—an oral aromatase inhibitor currently under development by REPRONOVO in collaboration with Mereo BioPharma.

Factors Affecting the Hypogonadism Market Growth

Rising Prevalence of Hypogonadism and Associated Disorders

The increasing incidence of testosterone deficiency driven by aging populations, obesity, diabetes, and other metabolic disorders is significantly expanding the patient pool and driving demand for hypogonadism therapies.

Growing Awareness and Improved Diagnosis Rates

Improved awareness among physicians and patients, along with wider availability of hormone testing and diagnostic tools, is leading to earlier and more accurate detection of hypogonadism, supporting market expansion.

Advancements in Testosterone Replacement Therapies

Innovation in treatment options such as long-acting injectables, transdermal gels, and oral formulations is improving patient convenience, adherence, and overall treatment uptake, thereby boosting market growth.

Increasing Focus on Men’s Health and Lifestyle Diseases

Rising awareness of men’s health issues and the strong link between hypogonadism and chronic conditions like metabolic syndrome and infertility are further accelerating diagnosis and treatment adoption.

Expansion of Healthcare Infrastructure and Access

Improved healthcare access, especially in emerging markets, along with greater physician adoption of hormone therapies, is broadening the treated population base and supporting market growth.

Request a sample to unlock the CAGR for "Hypogonadism Market Forecast "

DelveInsight's “Hypogonadism – Market Insight, Epidemiology and Market Forecast – 2036” report delivers an in-depth analysis of hypogonadism epidemiology, market, and clinical development in hypogonadism. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the hypogonadism market trends in the United States, EU4 (Germany, France, Italy, and Spain ), the United Kingdom, and Japan.

Hypogonadism market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted hypogonadism market size from 2020 to 2034 in 7MM. The report also covers current hypogonadism treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Hypogonadism Disease Understanding

Hypogonadism Overview

Hypogonadism is a medical condition characterized by reduced or absent production of sex hormones, primarily testosterone in males and estrogen/progesterone in females, due to dysfunction of the gonads (testes or ovaries) or the hypothalamic-pituitary axis. It can be classified as primary (originating from the gonads) or secondary (originating from the brain’s hormonal regulation centers). Common symptoms include reduced libido, infertility, fatigue, muscle loss, mood changes, and in males, erectile dysfunction and decreased body hair.

Hypogonadism Diagnosis

The diagnosis of hypogonadism involves clinical evaluation supported by laboratory hormone testing. Key diagnostic tests include serum testosterone levels (usually measured in the morning), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin levels. Imaging studies such as MRI of the pituitary gland may be performed in suspected secondary hypogonadism. Additional assessments may include semen analysis in males and bone density tests to evaluate long-term complications.

Hypogonadism Treatment

Treatment for hypogonadism focuses on restoring hormone balance and addressing underlying causes. Testosterone replacement therapy (TRT) is commonly used in males through injections, gels, patches, or oral formulations. In secondary hypogonadism, therapies may include gonadotropin or GnRH-based treatments to stimulate natural hormone production. Lifestyle modifications such as weight management, exercise, and treatment of underlying conditions like obesity or diabetes also play a key role in improving outcomes and overall hormonal health.

Hypogonadism Epidemiology

The hypogonadism epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total prevalent cases of hypogonadism, total diagnosed prevalent cases of hypogonadism, type-specific diagnosed prevalent cases of hypogonadism, age-specific diagnosed prevalent cases of hypogonadism, gender-specific diagnosed prevalent cases of hypogonadism, and total treatable cases of hypogonadism in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034. 

Key Findings from Hypogonadism Epidemiological Analyses and Forecast

• According to studies conducted by Galdiero and Longhi (2024), approximately 40% of men older than 45 and 50% of men in their 80s are hypogonadal.
• A recent study in nonobese diabetic males found that 29% were testosterone deficient. The visceral adiposity index was the only reliable indicator of testosterone deficiency in this group of patients.
• According to secondary research, hypogonadism is a common condition in the male population, with a higher prevalence in older men, obese men, and men with type 2 diabetes. It is estimated that approximately 35% of men older than 45 years of age and 30–50% of men with obesity or type 2 diabetes have hypogonadism.
• As per secondary research, Klinefelter's syndrome is the most common cause of primary hypogonadism and is reported in 1:660 male births according to data from newborn screening.

Hypogonadism Drug Analysis

The drug chapter segment of the hypogonadism report encloses a detailed analysis of hypogonadism-marketed drugs and emerging pipeline drugs. It also deep dives into hypogonadism’s pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Hypogonadism Marketed Drugs

TLANDO (testosterone undecanoate): Lipocine and Verity Pharmaceuticals

TLANDO is approved by the FDA as a Testosterone Replacement Therapy (TRT) in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). It was developed using Lipocine's proprietary Lip'ral drug delivery technology platform.

In March 2022, the US Food and Drug Administration (FDA) approved TLANDO in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. 

Earlier, Lipocine licensed the exclusive US commercialization rights for TLANDO to Antares Pharma.

In January 2024, Lipocine, Gordon Silver Limited, and Verity Pharmaceuticals entered into an exclusive licensing agreement granting Verity Pharmaceuticals the rights to market TLANDO in the United States and Canada, following the termination of the prior license agreement with Antares, which became effective on January 31, 2024, thereby transferring all rights in TLANDO from Antares to Verity Pharmaceuticals.

JATENZO (testosterone undecanoate): Tolmar Pharmaceuticals

JATENZO capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, like primary hypogonadism and hypogonadotropic hypogonadism (congenital or acquired). Safety and efficacy of JATENZO in males less than 18 years old have not been established.

In March 2019, the US FDA approved JATENZO to treat men with certain forms of hypogonadism.

In October 2022, Tolmar Pharmaceuticals acquired all rights to JATENZO from Clarus Therapeutics and its wholly-owned subsidiary.

Note: Detailed current therapies assessment will be provided in the full report of hypogonadism

Hypogonadism Emerging Drugs

RPN-001 (leflutrozole): REPRONOVO and Mereo BioPharma

RPN-001 is a novel orally administered compound being developed for the treatment of infertility in men with low serum testosterone. ReproNovo has an exclusive global license agreement with Mereo BioPharma for the development and commercialization of leflutrozole.

In July 2025, ReproNovo announced the inclusion of the first participant in the company’s Phase II clinical trial of its lead candidate RPN-001 in development for the treatment of male infertility.

Hypogonadism Drug Class Insights

Aromatase inhibitors help treat hypogonadism by blocking the enzyme aromatase, which is responsible for converting testosterone into estrogen (estradiol). By inhibiting this conversion, aromatase inhibitors reduce estrogen levels and thereby increase the amount of circulating testosterone in the body. This leads to an improved testosterone-to-estrogen ratio, which can help alleviate symptoms of hypogonadism, particularly in men where low testosterone and relatively high estrogen levels are problematic.

Hypogonadism Market Outlook

Asymptomatic hypogonadal patients generally do not require treatment, and therapy is reserved for those with symptoms linked to low testosterone. Testosterone replacement options include subcutaneous pellets such as TESTOPEL, as well as nasal and buccal formulations, though their use is limited due to local irritation and restricted data. Oral testosterone undecanoate (ANDRIOL) is available outside the US but shows variable serum levels and requires fatty meals. New self-emulsifying formulations are in development. Recent options include transdermal gels like TESTOCUR and creams such as AndroForte, offering improved tolerability and comparable efficacy. Non-testosterone therapies and emerging SARMs may further expand future treatment options.

Hypogonadism Competitive Landscape

The Hypogonadism market is highly competitive and moderately consolidated, dominated by major pharmaceutical companies and supported by several emerging players focused on improving testosterone replacement therapies (TRT). The competitive environment is driven by innovation in drug delivery systems, increasing investment in men’s health, and strong emphasis on improving patient adherence and safety profiles.

Key Hypogonadism Market Companies

The Hypogonadism Market companies developing therapies include -

• AbbVie Inc.,
• Pfizer Inc.,
• Endo Pharmaceuticals,
• Teva Pharmaceutical Industries Ltd.,
• Eli Lilly and Company,
• Bayer AG,
• Ferring Pharmaceuticals,
• Sun Pharmaceutical Industries Ltd.,
• Viatris Inc, and others.

Hypogonadism Drugs Uptake

This section focuses on the uptake rate of potential Hypogonadism therapies expected to be launched in the market during 2024–2034. The adoption of emerging therapies will depend on the evolving Hypogonadism competitive landscape, clinical efficacy and safety outcomes, pricing strategies, reimbursement availability, patient preference for formulation type, and order of market entry. Key Hypogonadism companies developing novel testosterone replacement and non-testosterone therapies through pivotal and confirmatory clinical studies must carefully design trial endpoints and comparator strategies to enhance regulatory success, accelerate approvals, and support rapid market uptake across the 7MM.

Hypogonadism Clinical Trial Activities

The Hypogonadism pipeline report provides comprehensive insights into ongoing and completed clinical trials across Phase III, Phase II, and early-stage development. The report highlights major Hypogonadism companies involved in developing innovative therapies including advanced testosterone formulations, selective androgen receptor modulators (SARMs), and alternative hormone stimulation approaches aimed at improving efficacy, safety, and patient convenience.

Hypogonadism Pipeline Development Activities

The Hypogonadism clinical trial analysis report covers detailed information regarding strategic collaborations, mergers and acquisitions, licensing agreements, partnerships, regulatory milestones, and patent activities associated with emerging Hypogonadism therapies. The report also evaluates pipeline expansion strategies and recent advancements adopted by pharmaceutical and biotechnology companies operating within the Hypogonadism treatment landscape.

Latest KOL Views on Hypogonadism

To understand the real-world treatment landscape and evolving market trends, insights are gathered from Key Opinion Leaders (KOLs) and industry experts through primary research. These expert opinions help validate secondary research findings and provide a better understanding of current treatment approaches, patient eligibility criteria (symptomatic vs asymptomatic), therapy-switching patterns, preference for delivery systems (injectables, gels, oral, nasal), and expected uptake of novel Hypogonadism therapies.

DelveInsight’s analysts interacted with multiple KOLs and subject matter experts across the 7MM to gain insights into the evolving Hypogonadism treatment environment. Their perspectives support the identification of unmet medical needs, emerging therapeutic opportunities, and the future impact of upcoming therapies on overall market dynamics.

Hypogonadism Drugs Market Qualitative Analysis

The Hypogonadism report performs qualitative and market intelligence analysis using analytical frameworks such as SWOT analysis and Conjoint Analysis. SWOT analysis evaluates strengths, weaknesses, opportunities, and threats associated with disease awareness, diagnosis rates, physician acceptance, treatment accessibility, cost-effectiveness, and the overall Hypogonadism competitive landscape.

Conjoint Analysis assesses approved and emerging therapies based on key attributes including efficacy, safety profile, route of administration, dosing convenience, patient adherence, and expected order of market entry. Therapies are scored across these parameters to evaluate their overall clinical and commercial potential.

Additionally, therapy safety and tolerability are assessed based on adverse events, long-term hormonal stability, cardiovascular risk considerations, and patient acceptability observed during clinical studies. The analysis also incorporates probability of success and addressable patient population to determine the overall ranking and weightage of emerging therapies within the Hypogonadism market.

Hypogonadism Therapeutics Market Access and Reimbursement

The Hypogonadism therapeutics market report further provides detailed insights into country-wise market accessibility, reimbursement frameworks, and cost-effectiveness of currently available therapies. The report also highlights patient support programs, insurance coverage under public and private healthcare systems, reimbursement challenges, and initiatives aimed at improving patient affordability and access to advanced Hypogonadism therapies across the major markets.

Scope of the Hypogonadism Market Report

• The Hypogonadism Market report covers a segment of key events, an executive summary, a descriptive overview of hypogonadism, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the hypogonadism market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Hypogonadism Market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM hypogonadism market.

Hypogonadism Market Report Insights

• Hypogonadism Patient Population
• Hypogonadism Market Therapeutic Approaches
• Hypogonadism Pipeline Analysis
• Hypogonadism Market Size and Trends
• Existing and Future Hypogonadism Market Opportunity 

Hypogonadism Market Report Key Strengths

• Ten-Year Forecast
• 7MM Coverage 
• Hypogonadism Epidemiology Segmentation
• Hypogonadism Market Key Cross Competition 
• Hypogonadism Market Conjoint Analysis
• Drugs Uptake and Key Hypogonadism Market Forecast Assumptions

Hypogonadism Market Report Assessment

• Current Hypogonadism Treatment Practices
• Hypogonadism Market Unmet Needs
• Hypogonadism Pipeline Product Profiles
• Hypogonadism Market Attractiveness
• Hypogonadism Qualitative Analysis (SWOT and Conjoint)

FAQs

Hypogonadism Therapeutics Market Insights

• What was the hypogonadism total market size, the market size by therapies, the market share (%) distribution in 2024, and what would it look like in 2034? What are the contributing factors for this growth?
• At what CAGR, the hypogonadism market is expected to grow at the 7MM level during the study period (2020–2034)?
• How is Japan's hypogonadism competitive landscape evolving? 
• What are the disease risks, burdens, and unmet needs of hypogonadism? 
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to hypogonadism?
• What is the historical and forecasted hypogonadism patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What factors are affecting the increase in the diagnosis of symptomatic cases?
• What are the current options for the treatment of hypogonadism? What are the current treatment guidelines for the treatment of hypogonadism in the US and Europe?
• How many companies are developing therapies for the treatment of hypogonadism?
• What key designations have been granted for the emerging therapies for hypogonadism?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.

Reasons to Buy the Hypogonadism Market Forecast Report 

• The  Hypogonadism Market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the hypogonadism market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand KOLs’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.